Professor Philip Newsome PhD, FRCPE

Philip Newsome

Department of Immunology and Immunotherapy
Honorary Professor of Experimental Hepatology and Honorary Consultant Hepatologist

Contact details

Email
p.n.newsome@bham.ac.uk
Sharona Rowe, Executive Assistant
s.rowe@researchinliver.org.uk
Address
Centre for Liver and Gastrointestinal Research
5th Floor, Institute of Biomedical Research
Department of Immunology and Immunotherapy
College of Medicine and Health
黑料吃瓜网
Edgbaston
Birmingham
B15 2TT
UK

Professor Philip Newsome was Director of the Innovate UK funded , Secretary General of the European Association for the Study of the Liver (EASL) and was Director of the  until June 2024.

Philip has published over 150 major research papers in scientific journals as well as reviews and book chapters in the fields of stromal cell biology and liver disease. He has received major grants from Innovate UK, NIHR, European Commission, Wellcome Trust, UKSCF, BBSRC and the Medical Research Council.

He is an enthusiastic communicator on the theme of translational cell therapy work and non-alcoholic fatty liver disease and gives frequent talks to various groups at both the local and national level. He frequently contributes to both the local and national media and continues to advise the BBC on cell therapy related stories.

Qualifications

  • Fellowship of Royal College of Physicians Edinburgh 2009
  • PhD Medicine 2003
  • MBChB 1995
  • BSc (Hons) Neuroscience 1994

Biography

Philip Newsome is Honorary Professor of Experimental Hepatology and was Director of the Centre for Liver and Gastrointestinal Research. He was also Director of the Innovate-UK funded . He was Director of the and is the Chief Investigator on the EU FP7 funded MERLIN project as well as the Innovate UK funded POLARISE trial looking at mesenchymal stromal cells in liver disease.

He ran the metabolic services at the Liver Unit at the Queen Elizabeth Hospital Birmingham which included a large multi-disciplinary clinic for patients with NAFLD. He was Chief Investigator on a randomised controlled trial of Glucagon-like peptide-1 (GLP-1) therapy in NAFLD published in the Lancet, and is also Chief Investigator on a study of Fibroscan in NAFLD published in Gastroenterology. He is editor of a published textbook on Liver Transplantation, and chaired the national guidelines for abnormal liver blood tests. He sat on the NICE Guideline Development Group for NAFLD.

He was the Secretary General (President) for the European Association for the Study of the Liver which is the foremost Hepatology society in Europe. Its annual conference is the leading international meeting with >10,000 attendees.

He was the Hepatology vice-President for the British Society of Gastroenterology which is the foremost gastroenterology society in the UK.

Philip has received significant grant funding from the Innovate UK, NIHR, European Union, Wellcome Trust, UKSCF, BBSRC and the Medical Research Council. This research portfolio has led to high impact publications amongst over 100 major research papers in the fields of stem cell biology and liver disease. This has included original articles (PNAS, Hepatology, Journal of Hepatology, Gut, American Journal of Transplantation, Annals of Internal Medicine, Lancet) and review articles (Gastroenterology, Journal of Hepatology).

In June 2024, he moved to a new role in London, Director of Roger Williams Institute of Liver Studies, Director of King's Health Partners Centre for Translational Medicine, Professor of Hepatology at King’s College London, and Honorary Consultant Hepatologist at King’s College Hospital. 

Teaching

Programmes

A range of lectures on aspects of stem cell biology, stem cell contribution in liver injury, liver regeneration and disease modelling using genetically modified mice. These include stem cell courses for Biomedical Science BSc, and one-off lectures for a number of MBChB, MSc and BSc courses. He also provides bed-side teaching for clinical students.

Module lead on Biomedical Science BSc (liver disease and health).

Postgraduate supervision

Philip is interested in supervising doctoral research students in the following areas:

  • Contribution of adult stem cells to liver injury and repair.
  • Non-alcoholic fatty liver disease; ranging from laboratory to clinical studies.

If you are interesting in studying any of these subject areas please contact Professor Philip Newsome directly, or for any general doctoral research enquiries, please email mds-gradschool@contacts.bham.ac.uk.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings.

Research

Research themes

Stromal cell Biology, clinical trials, cell trafficking and non-alcoholic fatty liver disease.

Research activity

As a clinician scientist Phil’s research starts with cutting edge basic science work which is being successfully translated to the bedside by way of innovative therapeutic studies, such as the NIHR-funded clinical trial of stem cell therapy in patients with liver cirrhosis for which he is Chief Investigator. This was the largest randomised controlled trial of stem cell therapy thus far and was in collaboration with his colleague Stuart Forbes in Edinburgh.

Stem/stromal cell biology

The main emphasis of his group’s laboratory work over the last few years has been on the trafficking and role of both adult and embryonic stem cells in the context of liver injury. This has allowed identification of the key molecular interactions that regulate the successful engraftment of such cells into the liver.

Non-alcoholic fatty liver disease

Additionally he has a bench to bedside programme of research in non-alcoholic fatty liver disease (NAFLD). He is clinical lead for the metabolic liver service at UHBNFT and was Chief Investigator on a Wellcome Trust funded randomised double-blinded placebo controlled trial of Liraglutide (novel Glucagon-like peptide-1 analogue) in patients with NAFLD published in the Lancet. This was an Investigator initiated study performed in conjunction with an industrial partner (Novo Nordisk) and the University of Nottingham (Guru Aithal).

NAFLD is now the commonest cause of liver disease in the West, and for which again there are no effective therapies. He is the global Chief Investigator on multiple clinical trials of new therapeutic agents and leads on NAFLD for both the UK and EASL Lancet commissions on liver disease.

Other activities

  • Clinical lead for metabolic liver disease at the Liver Unit, University Hospital Birmingham NHS Foundation Trust (UHBNFT)
  • Expert advisor for the Association of Glycogen Storage Disorders

Publications

Recent publications

Article

Feng, G, M贸zes, FE, Ji, D, Treeprasertsuk, S, Okanoue, T, Shima, T, Liang, H, Tsochatzis, E, Chen, J, Schattenberg, JM, Labenz, C, Mahadeva, S, Chan, WK, Chi, X, Delamarre, A, de L茅dinghen, V, Petta, S, Bugianesi, E, Hagstr枚m, H, Boursier, J, Calleja, JL, Boon-Bee Goh, G, Gallego-Dur谩n, R, Sanyal, AJ, Fan, J-G, Cast茅ra, L, Lai, M, Harrison, SA, Romero-Gomez, M, Kim, SU, Zhu, Y, Ooi, G, Shi, J, Yoneda, M, Nakajima, A, Lupsor-Platon, M, Zhong, B, Cobbold, JFL, Ye, C-Y, Eddowes, PJ, Newsome, P, Li, J, George, J, He, F, Song, MJ, Tang, H, Fan, Y, Jia, J, Xu, L, Lin, S, Li, Y, Lu, Z, Nan, Y, Niu, J, Yan, X, Zhou, Y, Liu, C, Deng, H, Ye, Q, Zeng, Q-L, Li, L, Wang, J, Yang, S, Lin, H, Lee, HW, Cheuk-Fung Yip, T, Fournier-Poizat, C, Lai-Hung Wong, G, Pennisi, G, Armandi, A, Liu, W-Y, Shang, Y, de Saint-Loup, M, Llop, E, Jun Teh, KK, Romero, CL, Asgharpour, A, Mahgoub, S, Sau-Wai Chan, M, Canivet, CM, Ji, F, Xin, Y, Chai, J, Dong, Z, Targher, G, Byrne, CD, He, N, Mi, M, Ye, F, Wai-Sun Wong, V, Pavlides, M, Zheng, M-H & Zhang, J 2024, '', Clinical Gastroenterology and Hepatology.

Harrison, SA, Bedossa, P, Guy, CD, Schattenberg, JM, Loomba, R, Taub, R, Labriola, D, Moussa, SE, Neff, GW, Rinella, ME, Anstee, QM, Abdelmalek, MF, Younossi, Z, Baum, S, Francque, S, Charlton, M, Newsome, P, Lanthier, N, Shiefke, I, Mangia, A, Pericas, JM, Patil, R, Sanyal, AJ, Noureddin, M, Bansal, M, Alkhouri, N, Castera, L, Rudraraju, M, Ratziu, V & MAESTRO-NASH Investigators 2024, '', The New England Journal of Medicine, vol. 390, pp. 497-509.

Khan, R, Salman, S, Harford, L, Sheriff, L, Hazeldine, J, Rajoriya, N, Newsome, PN & Lalor, PF 2024, '', Frontiers in immunology, vol. 15, 1330536.

Horn, P, Norlin, J, Almholt, K, Viuff, BM, Galsgaard, ED, Hald, A, Zosel, F, Demuth, H, Poulsen, S, Norby, PL, Rasch, MG, Vyberg, M, Fleckner, J, Werge, MP, Gluud, LL, Rink, MR, Shepherd, E, Northall, E, Lalor, PF, Weston, CJ, Fog-Tonnesen, M & Newsome, PN 2024, '', eLife, vol. 13, RP95185.

Newsome, PN, Sanyal, AJ, Engebretsen, KA, Kliers, I, 脴stergaard, L, Vanni, D, Bugianesi, E, Rinella, ME, Roden, M & Ratziu, V 2024, '', Alimentary Pharmacology & Therapeutics.

Miller, H, Harman, D, Aithal, GP, Manousou, P, Cobbold, JF, Parker, R, Sheridan, D, Newsome, PN, Karpe, F, Neville, M, Arlt, W, Sitch, AJ, Korbonits, M, Biehl, M, Alazawi, W & Tomlinson, JW 2024, '', BMJ open, vol. 14, no. 1, e074918.

Hirschfield, G, Arndtz, K, Kirkham, A, Chen, Y-Y, Fox, R, Rowe, A, Douglas-Pugh, J, Thorburn, D, Barnes, E, Aithal, GP, Hull, D, Bhandal, K, Olsen, K, Woodward, P, Lax, S, Newsome, P, Smith, D, Kallio, A, Adams, D, Homer, V & Weston, C 2024, '', Hepatology Communications, vol. 8, no. 5, e0426.

VCTE-Prognosis Study Group, Lin, H, Lee, HW, Yip, TC-F, Tsochatzis, E, Petta, S, Bugianesi, E, Yoneda, M, Zheng, M-H, Hagstr枚m, H, Boursier, J, Calleja, JL, Goh, GB-B, Chan, W-K, Gallego-Dur谩n, R, Sanyal, AJ, de L茅dinghen, V, Newsome, P, Fan, J-G, Cast茅ra, L, Lai, M, Harrison, SA, Fournier-Poizat, C, Wong, GL-H, Pennisi, G, Armandi, A, Nakajima, A, Liu, W-Y, Shang, Y, de Saint-Loup, M, Llop, E, Teh, KK-J, Lara-Romero, C, Asgharpour, A, Mahgoub, S, Chan, MS-W, Canivet, CM, Romero-Gomez, M, Kim, SU & Wong, VW-S 2024, '', JAMA - Journal of the American Medical Association.

Lazarus, JV, Mark, HE, Allen, AM, Arab, JP, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, SA, Anstee, QM, Arrese, M, Bataller, R, Berg, T, Brennan, PN, Burra, P, Castro-Narro, GE, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, SM, Gastaldelli, A, Hagstr枚m, H, Huang, TTK, Ivancovsky Wajcman, D, Kautz, A, Kopka, CJ, Krag, A, Newsome, PN, Rinella, ME, Romero, D, Sarin, SK, Silva, M, Spearman, CW, Terrault, NA, Tsochatzis, EA, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, JM, Wong, VW-S & Younossi, ZM 2023, '', Hepatology.

Healthy Livers, Healthy Lives Collaborators, Lazarus, JV, Mark, HE, Allen, AM, Arab, JP, Carrieri, P, Noureddin, M, Alazawi, W, Alkhouri, N, Alqahtani, SA, Arrese, M, Bataller, R, Berg, T, Brennan, PN, Burra, P, Castro Narro, GE, Cortez-Pinto, H, Cusi, K, Dedes, N, Duseja, A, Francque, SM, Hagstr枚m, H, Huang, TT-K, Wajcman, DI, Kautz, A, Kopka, CJ, Krag, A, Miller, V, Newsome, PN, Rinella, ME, Romero, D, Sarin, SK, Silva, M, Spearman, CW, Tsochatzis, EA, Valenti, L, Villota-Rivas, M, Zelber-Sagi, S, Schattenberg, JM, Wong, VW-S & Younossi, ZM 2023, '', Journal of Hepatology, vol. 79, no. 3, pp. 618-634.

BI 1467335 NASH Phase IIa trial team 2023, '', Nature Communications, vol. 14, no. 1, 7151.

Comment/debate

Newsome, P, Rinella, ME, Lazarus, JV & Terrault, N 2024, '', Hepatology, vol. 79, no. 1, pp. E5-E6.

Rinella, ME, Castro Narro, GE, Krag, A, Terrault, N & Newsome, PN 2024, '', Hepatology, vol. 79, no. 2, pp. E16-E17.

Review article

Abeysekera, KWM, Valenti, L, Younossi, Z, Dillon, JF, Allen, AM, Nourredin, M, Rinella, ME, Tacke, F, Francque, S, Gin猫s, P, Thiele, M, Newsome, PN, Guha, IN, Eslam, M, Schattenberg, JM, Alqahtani, SA, Arrese, M, Berzigotti, A, Holleboom, AG, Caussy, C, Cusi, K, Roden, M, Hagstr枚m, H, Wong, VWS, Mallet, V, Castera, L, Lazarus, JV & Tsochatzis, EA 2024, '', The Lancet Gastroenterology and Hepatology, vol. 9, no. 1, pp. 83-91.

NAFLD Nomenclature consensus group 2023, '', Journal of Hepatology, vol. 79, no. 6, pp. 1542-1556.

Expertise

Stem cell research for liver disease; clinical interest in fatty liver disease and liver transplantation; metabolic liver disease (cystic fibrosis, porphyria, glycogen storage disease).